Cited by 356Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchAntiplatelet Therapy and Cardiovascular Diseases

The DOI matches its Crossref record, with a small difference in title or year; 9 of the 9 references it cites were found in a registry or an index.

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Open access

Ray, Kausik K., Cannon, Christopher P., McCabe, Carolyn H., Cairns, Richard, Tonkin, Andrew M., Sacks, Frank M., Jackson, Graham, Braunwald, Eugene·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.03.077

Open this paper in CoChat — free account Open PDF

Abstract

Objectives Our objective was to determine the timing of benefit with intensive statin therapy after an acute coronary syndrome (ACS) in two time windows: an early window soon after an ACS and a late window in more stable patients.Background The Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial showed that the use of intensive statin therapy improved clinical outcomes over two years in ACS patients versus standard therapy. The relative contributions of early or late effects to the overall clinical efficacy of intensive therapy are presently unclear.Methods A total of 4,162 patients with ACS were recruited in the PROVE IT-TIMI 22 trial. Patients were randomized to intensive statin therapy (atorvastatin, 80 mg) or standard therapy (pravastatin, 40 mg). The composite triple end point of death, MI, or rehospitalization for recurrent ACS was determined in each group at 30 days. The composite triple and primary end points were assessed in stable patients from six months to the end of study, after censoring for clinical events before six months.Results The composite end point at 30 days occurred in 3.0% of patients receiving atorvastatin 80 mg versus 4.2% of patients receiving pravastatin 40 mg (hazard ratio [HR] = 0.72; 95% confidence interval [CI], 0.52 to 0.99; p = 0.046). In stable patients, atorvastatin 80 mg was associated with a composite event rate of 9.6% versus 13.1% in the pravastatin 40 mg group (HR = 0.72; 95% CI, 0.58 to 0.89; p = 0.003).Conclusions Intensive statin therapy early after ACS leads to a reduction in clinical events at 30 days, consistent with greater early pleiotropic effects. In stable patients, intensive statin therapy provides long-term reduction in clinical events when compared with standard therapy. Thus, ACS patients should be started in-hospital and continued long-term on intensive statin therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.03.077

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citation
Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban
Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Vicari, R. M., Frey, M. J., Lakkis, N. M., Neumann, F., Robertson, D. H., DeLucca, P. T., DiBattiste, P. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442501 · Cited by 2,093
Self-citation
Antibodies to glutamic acid decarboxylase as predictors of insulin-dependent diabetes mellitus before clinical onset of disease
Tuomilehto, J., Vidgrén, G., Toivanen, L., Tuomilehto‐Wolf, E., Kohtamäki, K., Stengård, J., Zimmet, P., Mackay, I. R., Rowley, M. J., & Koskela, P. U. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92521-6 · Cited by 1,691
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Effect of Partial Ileal Bypass Surgery on Mortality and Morbidity from Coronary Heart Disease in Patients with Hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Pathological Changes in Acute Coronary Syndromes: The Role of Statin Therapy in the Modulation of Inflammation, Endothelial Function and Coagulation
Ray, K., & Cannon, C. (2004) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-004-0205-9 · Cited by 43
Self-citation

Flagged first, then by citations

Show all 9 references

Research works printed but not linked: 1

1994, Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease, Lancet, 344, 1383

Sorted by citations

Items 301–356 of 356

Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
ACS AND ANTIPLATELET MANAGEMENT: UPDATED GUIDELINES AND CURRENT TRIALS
Cannon, C. P. (2007)
Self-citation
Skuteczność połączenia ezetymibu/simwastatyny w dawkach 10/40 mg w porównaniu z podwójną dawką statyny u pacjentów hospitalizowanych z powodu ostrego incydentu wieńcowego: badanie INFORCE
Reckless, J. P. D., Henry, P., Pomykaj, T., Lim, S., Massaad, R., Vandormael, K., Johnson‐Levonas, A. O., Lis, K., Brudi, P., & Allen, C. (2009) · Via Medica Journals
Guía europea sobre prevención de la enfermedad cardiovascular en la práctica clínica (versión 2012) Quinto Grupo de Trabajo de la Sociedad Europea de Cardiología y otras Sociedades sobre la Prevención de la Enfermedad Cardiovascular en la Práctica Clínica (constituido por representantes de nueve sociedades y expertos invitados)
Perk, J. (2012)
UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE:
Cardiovasculares, C. E. C., & Medicina, F. D. (2009)
Dyslipidémies et risque cardiovasculaire : données des études de prévention cardiovasculaire
Farnier, M. (2010) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(10)51267-8
From statin efficacy to everyday effectiveness: Studying the gap in between.
Ruokoniemi, P. T. (2015) · UTUPub (University of Turku)
FLUXO CORONARIANO, MICROEMBOLIA E OBSTRUÇÃO MICROVASCULAR APÓS TROMBOSE CORONARIANA AGUDA E REPERFUSÃO CORONÁRIA CORONARY FLOW, MICROVASCULAR OBSTRUCTION AND MICROEMBOLIZATION AFTER ACUTE CORONARY THROMBOSIS AND CORONARY REPERFUSION
Seixas, E. D. A. (2010)
Prevalência de alta reatividade plaquetária em pacientes tratados com aspirina encaminhados para angiografia coronária Prevalence of high platelet reactivity in aspirin-treated patients referred for coronary angiography
Manica, A., Sarmento‐Leite, R., Manfroi, C., Rodrigues, L. H., Jr., Gottschall, C. A. M., Marchini, J. F., & Croce, K. (2013) · DOAJ (DOAJ: Directory of Open Access Journals)
New paradigm of treatment with statins in cardiovascular prevention
Vigorito, C., & Chieffo, C. (2016) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2009.320
Ghidul european de prevenţie a bolilor cardiovasculare în practica clinică (versiunea 2012) Al Cincilea Comitet al Societăţii Europene de Cardiologie şi a altor Societăţi de Prevenţie a Bolilor Cardiovasculare în Practica Clinică (constituit din reprezentanţi ai nouă societăţi şi experţi invitaţi) Dezvoltat cu contribuţia specială a Asociaţiei Europene pentru Prevenţie şi Reabilitare Cardiovasculară (EACPR)
Perk, J. (2014)
The clinical and cost-effectiveness of intensive versus standard lipid lowering with statins in the prevention of cardiovascular events amongst patients with acute coronary syndromes: a systematic review
Greenheld, W., Wilson, J., Bayliss, S. E., & Hyde, C. (2007)
Management of Associated Cardiovascular Risk in Essential Hypertension
Papademetriou, V. (2008) · Elsevier eBooks · doi:10.1016/b978-141605484-9.50058-7
Inflammation and Immunity as Targets for Drug Therapy in Acute Coronary Syndrome
Jolicoeur, M. E., & Granger, C. B. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-4927-2.00025-6
Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes
Kostner, K., Nicholls, S. J., Amerena, J. V., Brown, A. D. H., Cooper, M. E., Hammett, C., O’Brien, R. C., Kritharides, L., Hare, D. L., Watts, G. F., et al. (2016) · Heart Lung and Circulation · doi:10.1016/j.hlc.2016.09.005
Economic Aspects of Adherence to Hyperlipidemia Treatment in Sweden
Hallberg, S. (2014)
Statins in ACS Patients: Intensity of Treatment, Timing of Benefit
Herrmann, H. C. (2005) · Journal watch · doi:10.1056/jc200512090000002
PharmacotherapyFirst: A Multimedia Learning Resource
Munyer, T. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst
Free triiodothyronine level correlates with statin responsiveness in acute myocardial infarction.
Wy, W., Zhang, K., Zhao, W., Gerdes, A., Iervasi, G., & Yd, T. (2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.04.009
Non ST-Elevation Acute Coronary Syndromes
Wiviott, S. D., & Giugliano, R. P. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50016-4
Protection of Microcirculation during PCI
Pande, A., & Chakraborty, R. (2017) · Jaypee Brothers Medical Publishers (P) Ltd. eBooks · doi:10.5005/jp/books/13035_18
Non–ST-Segment Elevation Acute Coronary Syndromes
Wiviott, S. D., & Giugliano, R. P. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00009-6
HYPOLIPIDEMIC THERAPY BY STATINS IN ACUTE CORONARY SYNDROME
Tsibulskaya, N. Y., Kharkov, E. I., & Петрова, М. М. (2018) · Siberian medical review · doi:10.20333/2500136-2018-6-22-32
Lipid-independent Pleiotropic Effects Lipid-independent Pleiotropic Effects of Statins in the Management of Acute of Statins in the Management of Acute Coronary Syndromes Coronary Syndromes
Ray, K. K., & Cannon, C. P. (2007)
Self-citation
Concentration of Lp-PLA2 in stable patients in secondary prevention after STEMI and dose-effect of statins on its values
Pařenicová, I., Prymusová, K., Beňovská, M., Babušíková, L., Jarkovský, J., Dostálová, L., Kubková, L., Lokaj, P., Kala, P., Poloczek, M., et al. (2011) · Cor et Vasa · doi:10.33678/cor.2011.175
New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases
Gilyarevsky, S. R., Golshmid, M. V., Kuzmina, I. M., & Sinitsina, I. I. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-16-110-117
CONTROL OF CARDIOVASCULAR RISK FACTORS IN PATIENTS AFTER MYOCARDIAL INFARCTION
Pęksa, J. W., Jankowski, P., & Czarnecka, D. (2019) · Wiadomości Lekarskie · doi:10.36740/wlek201903129
Effect of atorvastatin on the lipid profile, markers of immune inflammation and symptomatic severity of heart failure in patients with myocarditis
Рыжман, Н. Н., Гришаев, С. Л., Cherkashin, D. V., Гладышева, Э. В., Filippov, V. Y., & Кутелев, Г. Г. (2020) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma50538
The efficacy of the combined antihypertensive and statin therapy in patients with hypertension and excessive body mass
Petrik, N. I., Syrmilo, N. N., & Kovalyova, A. A. (2020) · Ukrainian Therapeutical Journal · doi:10.30978/utj2020-4-31
Efficiency of high-intensity therapy with rosuvastatin for secondary prevention of cardiovascular complications in patients with a very high risk
Евгеньевна, К. Т., Алексеева, И. А., Tmoyan, N. A., & Владиславович, Е. М. (2022) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2021-11-2-56-75
Chapter 1: Introduction
(2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000277985.25720.16
Dyslipidemia
McGiness, T. P., Holbert, H., Hentrich, L., & Waite, L. H. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.lipid_overview
Research Highlights
Aldridge, M. E., Elsayed, S. S., Somma, K., Chana, A., Shavelle, D. M., & Matthews, R. V. (2010) · Interventional Cardiology · doi:10.2217/ica.10.44
Evidently…
Lehman, R. (2006) · BMJ Evidence-Based Medicine · doi:10.1136/ebm.11.2.41
Hallmark Clinical Trials
(2007) · Humana Press eBooks · doi:10.1007/978-1-59745-238-0_22
Stable Angina
Roble, S. L. (2020) · Springer eBooks · doi:10.1007/978-3-030-28328-5_8
Hyperlipidemia
Waite, L. H., & McGiness, T. P. (2017) · The American Pharmacists Association eBooks · doi:10.21019/pharmacotherapyfirst.hyperlipidemia_overview
The relationship between acute cardiac attack and LDL-C serum levels in cardiac and CCU inpatients in Hajar hospital: Replying to a paradox
Lotfizadeh, M., Khaledifar, A., Heidari, F., & Khdemi, A. (2022) · Journal of Shahrekord University of Medical Sciences · doi:10.34172/jsums.2022.23
Special Patient Populations
Schwartz, G. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00036-4
TIME-DEPENDENT FACTORS OF EFFECTIVENESS AND TOLERABILITY OF STATINS: SCIENTIFIC AND PRACTICAL ASPECTS
Гиляревский, С. Р. (2018) · Eurasian heart journal · doi:10.38109/2225-1685-2018-3-62-75
High-Intensity Statins in Acute Coronary Syndrome Part 1: A look at the pharmacological properties of Statins and clinical trials on Statins in ACS
Kumar, M., Mani, U. A., Abbas, H., & Gupta, P. (2023) · Hypertension Journal · doi:10.61081/htnj/23v9i203
Detailed Lipid Profiles and Lipid-related Residual Risk after 12-week 10 mg Rosuvastatin Treatment for Acute Myocardial Infarction
Kondo, Y., Ishida, M., Ishisone, T., Niiyama, M., Osaki, T., Matsumoto, Y., Maegawa, Y., Sasaki, K., Ninomiya, R., Takahashi, Y., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3476-24
THE ROLE OF STATINS IN REDUCING THE RISK OF NO-SLOW-REFLOW BY CORONARY REVASCULARISATION
Александровна, Х. А., Вячеславович, С. Г., & Znamenskaya, I. (2023) · Vrach · doi:10.29296/25877305-2023-03-09
Clinical Importance of Optimal Medical Therapy on the Clinical Outcomes of Patients with Acute Myocardial Infarction after Percutaneous Coronary Intervention
Shimono, H., Tokushige, A., Kanda, D., Arikawa, R., Okui, H., Oketani, N., & Ohishi, M. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5192-24
Effectiveness and safety of long‐term therapy with alirocumab in acute coronary syndrome patients: A single‐centre retrospective real‐world study
Chen, L., Li, M., Deng, Y., Chen, Z., Huang, R., Yang, X., & Huang, Z. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70072
Некоторые аспекты практического применения Целевого обновления (2025) Рекомендаций Европейского общества кардиологов по лечению дислипидемий (2019)
Александровна, С. О. (2025) · Кардиология в Беларуси · doi:10.34883/pi.2025.17.5.008
Additional file 1 of Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
Kristensen, M. S., Green, A., Nybo, M., Hede, S. M., Mikkelsen, K. H., Gislason, G., Larsen, M. L., & Ersbøll, A. K. (2020) · Figshare · doi:10.6084/m9.figshare.12650719
Additional file 2 of Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study
Kristensen, M. S., Green, A., Nybo, M., Hede, S. M., Mikkelsen, K. H., Gislason, G., Larsen, M. L., & Ersbøll, A. K. (2020) · Figshare · doi:10.6084/m9.figshare.12650722
Evaluating the benefits of high-dose statin preloading in ST-segment elevation myocardial infarction management: insights from a systematic review and meta-analysis
Resende, B. L., Mata, E., Carlos, T., Português, J., Ribeiro, S., Gameiro, J., Lourenço, A., & Gonçalves, L. (2026) · Coronary Artery Disease · doi:10.1097/mca.0000000000001629
Statin Therapy Alters the Distribution of the LDL-C/HDL-C Ratio: A Weibull Modeling StudyPreprint
Nakayama, N., Imai, K., Niwa, S., Moriwaki, Y., Furukawa, N., & Hirai, M. (2026) · Research Square · doi:10.21203/rs.3.rs-9044847/v1
Singapore expert consensus on optimising lipid-lowering strategies in acute coronary syndrome: A modified Delphi study
Tan, R. S., Yap, J. J. L., Yeo, C., Poh, K. K., Yan, P. C., Chia, P. L., Lim, M. C. L., Foo, D. C. G., Jafary, F. H., & Koh, N. S. Y. (2026) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2025459
Chlamydia pneumoniae Seropositivity and Acute Coronary Syndromes: A Case–Control Study of the Infectious–Inflammatory Axis
Khalaf, L. F., Khalaf, R. F., Bagady, S. S., Khalaf, R. F., Amin, R. A., Manaa, A. O., Bagady, M. S., & Aljada, A. (2026) · Medicina · doi:10.3390/medicina62061107
Österreichischer Lipidkonsensus 2026
Kronenberg, F., Höllerl, F., Brath, H., Rega‐Kaun, G., Greber‐Platzer, S., Weiser, C., Klein, D. P., Riesenhuber, N., Binder, C. J., Brix, J. M., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02760-6
Top 10 Concepts in Secondary ASCVD Prevention From the 2026 ACC/AHA Dyslipidemia Guideline: What Is New and Why It Matters
Siddiqi, A. K., Jacob, J., Khan, M. S., & Kulkarni, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01465-5
Association of serum complement levels with failure of low-density-lipoprotein-cholesterol target attainment in patients after acute coronary syndrome: A prospective, observational study
Gogolas, V., Kyriazopoulou, E., Dagre, A. G., Ikonomidis, I., Olympios, C. D., Filippatos, G. S., Alexopoulos, D. K., & Rallidis, L. S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.09.026
Risk stratification in patients with heart failure and in patients with implantable cardioverter-defibrillators
Velavan, P. (2011) · Repository@Hull (Worktribe) (University of Hull)

Authors: Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
Monash University (AU)
Harvard University (US)
Guy's Hospital (GB)
Corresponding author: Cannon, Christopher P.
ORCID: Ray, Kausik K.
Cannon, Christopher P.
Tonkin, Andrew M.
Sacks, Frank M.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-10
Volume: 46
Issue: 8
Pages: 1405-1410
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.03.077
OpenAlex: W1484156179
Cited by: 356
References: 9
Citations by year: 2026: 10 · 2025: 13 · 2024: 5 · 2023: 12 · 2022: 13 · 2021: 4 · 2020: 15 · 2019: 11 · 2018: 17 · 2017: 15 · 2016: 14 · 2015: 11 · 2014: 18 · 2013: 20 · 2012: 24
FWCI: 26.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 2845 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Keywords: atorvastatin, acute coronary syndrome, high-intensity statin therapy, pravastatin, PROVE IT-TIMI 22, pleiotropy, myocardial infarction, hospital readmission, long-term clinical outcomes
MeSH terms: Atorvastatin, Acute Disease, Angina, Unstable, Double-Blind Method, Female, Heptanoic Acids, Humans, Male, Middle Aged, Myocardial Infarction, Pyrroles, Syndrome, Time Factors, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks